Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
This is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.
Lung Cancer, Non-Small Cell
BIOLOGICAL: Cobolimab|BIOLOGICAL: Dostarlimab|DRUG: Docetaxel
Overall survival (OS) in participants receiving cobolimab + dostarlimab + docetaxel relative to participants receiving docetaxel alone, OS is defined as survival from the date of randomization to the date of death by any cause., Up to approximately 52 months|OS in participants receiving dostarlimab + docetaxel relative to participants receiving docetaxel alone, OS is defined as survival from the date of randomization to the date of death by any cause., Up to approximately 52 months
OS in participants receiving cobolimab + dostarlimab + docetaxel relative to participants receiving dostarlimab + docetaxel, OS is defined as survival from the date of randomization to the date of death by any cause., Up to approximately 52 months|Objective response rate (ORR), Confirmed ORR is defined as the proportion of participants who have achieved confirmed complete response (CR) or confirmed partial response (PR), evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 based on Investigator assessment., Up to approximately 52 months|Progression free survival (PFS), PFS is defined as the length of time until disease progression, from the time of randomization to the earliest date of assessment of disease progression based on RECIST version 1.1 by Investigator assessment or death by any cause., Up to approximately 52 months|Duration of response (DOR), DOR is defined as the time from first documented response (CR/PR) until the time of first documentation of disease progression based on RECIST version 1.1 by Investigator assessment or death, whichever occurs first., Up to approximately 52 months|Time to deterioration (TTD), TTD in lung cancer is defined as time from randomization to meaningful deterioration on a composite endpoint of dyspnea, chest pain, and cough, from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 13 item Lung Cancer Module (EORTC QLQ LC13)., Up to approximately 52 months|Change from Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30 item Core Module (EORTC QLQ-C30) assessment, EORTC QLQ-C30 is a questionnaire used to measure health related quality of life (HRQoL) in participants with cancer., Baseline (Day 1) and up to approximately 52 months|Change from Baseline in the EORTC QLQ LC13 assessment, EORTC QLQ LC13 is a lung cancer specific questionnaire module designed to supplement the EORTC QLQ C30., Baseline (Day 1) and up to approximately 52 months|Number of participants with serious adverse events (SAEs), From consent signature (Day -28) until the 90 day post last dose follow-up|Number of participants with treatment-emergent adverse events (TEAEs) and immune related adverse event (irAEs), From consent signature (Day -28) until the 30 day post last dose follow-up|Number of participants with TEAEs leading to death, From consent signature (Day -28) until the 90 day post last dose follow-up|Number of participants with adverse events (AEs) leading to discontinuation, From consent signature (Day -28) until the 30 day post last dose follow-up|Number of participants with clinically significant changes in hematology, clinical chemistry, thyroid function and urinalysis lab parameters, Blood and urine samples will be collected for the assessment of hematology, clinical chemistry, thyroid function and urinalysis lab parameters, From consent signature (Day -28) until the 90 day post last dose follow-up|Number of participants with clinically significant changes in vital signs and Electrocardiogram (ECG) Parameters, From consent signature (Day -28) until the 90 day post last dose follow-up|Number of participants with indicated Eastern Cooperative Oncology Group (ECOG) performance status, Performance status will be assessed using the ECOG performance status scale. Scales range from grade 0 to 4, grade 0 denoting fully active and grade 4 completely disabled., From consent signature (Day -28) until the 90 day post last dose follow-up|Number of participants with usage of concomitant medications, From consent signature (Day -28) until the 90 day post last dose follow-up|Number of participants with abnormal physical examinations, From consent signature (Day -28) until the 90 day post last dose follow-up
This is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.